Clinical Trial Update: Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a combination of carfilzomib, rituximab, ifosfamide, carboplatin, and etoposide in relapsed or refractory stage I-IV diffuse large B-ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Carfilzomib (carfilzomib)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Rituximab (rituximab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-08-20